ClinicalTrials.gg
RecruitingNCT04237623Updated Oct 14, 2026

GM-CSF With Post-Transplant Cyclophosphamide

A Phase 2 interventional study of Sargramostim and Control Arm in Transplant-Related Hematologic Malignancy, sponsored by Northside Hospital, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Northside Hospital, Inc. · Phase 2, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2020; still recruiting 6 years 6 months later.
Updated Oct 14, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years to 78 Years
Sex
All
01

Study summary

Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.

02

Conditions studied

  • Transplant-Related Hematologic Malignancy
03

In context

Lead sponsor

Northside Hospital, Inc. is the lead sponsor of 27 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Availability of 5/10 to 8/10 matched related donor
  • >/= 70%
  • CML, AML, MDS, ALL, CLL, HD, NHL, MPS/CMML, MM, any other hematologic condition deemed an eligible indication for transplant by the treating center

Exclusion criteria

Exclusion Criteria:

  • Poor cardiac, pulmonary, liver, and renal function
  • -positive
  • Patients who have a debilitating medical or psychiatric illness that would preclude them from giving
  • History of severe or serious allergic reaction to human GM-CSF or yeast-derived products
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    GM-CSF post-transplant

    Sargramostim (GM-CSF) will start on Day +5 and continue until ANC \>1000 x3 days or \>1500 x1 day. GM-CSF will be administered not less than 24 hours after the last dose of cyclophosphamide and will be given at a dose of 250mcg/m2/day as an infusion over 2 hours.

    Drug: Sargramostim · Other: Control Arm

Interventions

  • 250mcg/m2/day IV starting Day +5

    Also known as: GM-CSF

  • OtherControl Arm

    Standard G-CSF given to those who decline to receive GM-CSF

    Also known as: G-CSF

06

What researchers measure

Primary outcomes

  1. The number of patients who achieved neutrophil engraftment at 20 days after the initiation of treatment.

    The aim of the study is to establish equivalent effectiveness of Sargramostim to a matched control cohort of G-CSF treated patients in time to achieve neutrophil (ANC \>500 x3 days) post infusion of HLA-mismatched peripheral blood haploidentical stem cells with post-transplant cyclophosphamide. Patients will be followed for 3 months following the initiation of treatment to see engraftment numbers at 20 days after initial treatment.

    Time frame: 3 months after initial treatment

Secondary outcomes

  1. How many patients are still alive measured by overall survival at 12 months following the initiation of treatment.

    To estimate overall survival

    Time frame: 12 months following initiation of treatment

  2. How many patients have not relapsed measured by relapse rates at 12 months following the initiation of treatment.

    To estimate relapse rates

    Time frame: 12 months following initiation of treatment

  3. How many patients develop graft-versus-host-disease (GVHD) measured by the incidence of GVHD at 12 months following initiation of treatment

    To estimate incidence of GVHD

    Time frame: 12 months following initiation of treatment

  4. How many patients have not relapsed measured by progression-free survival at 12 months following the initiation of treatment

    To estimate non-relapse mortality

    Time frame: 12 months following initiation of treatment

  5. How many patients died due to infections measured by the incidence and type of infections at 12 months following initiation of treatment

    To estimate infection-related mortality

    Time frame: 12 months following initiation of treatment

  6. How many patients died due to a treatment-related adverse events grade 2 or greater as assessed by CTCAE v.4.0

    To estimate event-free survival

    Time frame: 12 months following initiation of treatment

  7. Number of patients to achieve full donor chimerisms at Days 30, 50, 100, and 6 months post-transplant as measured by donor chimerism data

    To estimate graft failure

    Time frame: 12 months following initiation of treatment

  8. Number of patients that acquired an infection in the first 100-days post-transplant as measured by the incidence of infections

    To estimate the rate of infections

    Time frame: 12 months following initiation of treatment

  9. Number of patients achieving platelet engraftment as measured by platelets reaching 20,000 without transfusion for 7 days

    To assess time to platelet engraftment

    Time frame: 12 months following initiation of treatment

07

Study locations

1 of 1 sites recruiting
  • Northside Hospital
    Atlanta, Georgia 30342, United States
    Recruiting
    • Stacey Brown, BA · Contactstacey.brown@northside.com · 404-780-7965
    • Caitlin Guzowski, MBA, MHA · Contactcaitlin.guzowski@northside.com · 404-851-8523
    • H. Kent Holland, MD · Sub investigator
    • Asad Bashey, MD · Sub investigator
    • Lawrence E Morris, MD · Sub investigator
    • Scott Solomon, MD · Sub investigator
    • Melhem Solh, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2020 (actual). Primary completion is estimated for Dec 2026, 79 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2020
First posted
Jan 23, 2020
StartActual
May 18, 2020
Primary completionEst.
Dec 31, 2026was Sep 2026
CompletionEst.
Dec 31, 2027was Sep 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 18, 2026→Dec 31, 2026
Oct 14, 2026
Study completion
Sep 18, 2026→Dec 31, 2027
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Sep 18, 2026→Dec 31, 2026
    Study completion Sep 18, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04237623
Lead sponsor
Northside Hospital, Inc.
Responsible party
Sponsor
First posted
Jan 23, 2020
Start date
May 18, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Stacey Brown, BA
Contact
stacey.brown@northside.com
404-780-7965
Melhem Solh, MD
principal investigator · Northside Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sargramostim

Start the discussion